News|Articles|September 23, 2026

Implanted Antibiotic Reduced Systemic Regimen for Orthopedic Infection

Outcomes from treating orthopedic infection with debridement and implanted antibiotic were similar whether followed by short or standard duration of systemic antibiotic.

Patients with an orthopedic infection treated with debridement and an implanted antibiotic fared as well over 12 months whether they received a short (≤7 days) or standard duration (≥4 weeks) course of systemic antibiotic, according to the findings of a multicenter trial.1

"This trial challenges the standard of care for orthopedic infection, which usually includes at least 4 weeks of postoperative systemic antibiotic treatment," declare Martin McNally, MD, Bone infection Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals, Oxford, United Kingdom, and colleagues.

The investigators conducted the multi-center, open-label, noninferiority trial with 475 patients randomized on 1:1 basis to receive a short or standard duration of antibiotic treatment following debridement and implanted antibiotic for an orthopedic infection.457 participants remained eligible after vetting for trial protocol violations; with an additional 11 excluded for surgical site cultures resistant to the local antibiotic, and 3 in the long-duration group and 8 in the short-duration group lost to follow-up before 12 months.

The localized and systemic antibiotics were chosen by infectious disease specialists at the trial site.The implanted devices—either an absorbable or a polymethylmethacrylate (PMMA)-based carrier—eluted high antibiotic concentration at the infection site for at least 4 weeks.

The primary outcome was treatment failure within 12 months of surgery defined by the presence of at least one of the following: sinus tract or purulence at surgical site, microbiologic or histologic identification of infection at reoperation, newly elevated biomarkers in synovial fluid on aspiration or reoperation, or death from infection at the index surgical site. Secondary outcomes included potential antibiotic side effects and serious adverse effects.

McNally and colleagues reported definite treatment failure occurred within 1 year in 14.1% of patients in the long-duration group and in 11.1% in the short duration group, meeting the preset 10% difference criteria for non-inferiority.Overall survival at 12 months was 96.3% in the long-duration group and 97.9% in the short duration group.

What You Need to Know

In a 475-patient multicenter trial, a short (≤7 days) course of systemic antibiotics after debridement and local antibiotic implant was noninferior to a standard course (≥4 weeks) for preventing treatment failure in orthopedic infections at 12 months.

Treatment failure occurred in 14.1% of the long-duration group versus 11.1% of the short-duration group, meeting noninferiority criteria, while 12-month survival was similar between groups (96.3% vs. 97.9%).

The short-duration regimen was associated with notably fewer antibiotic-related adverse events (17.2% vs. 45.2% at 6 weeks) and a shorter average hospital stay, suggesting shorter systemic courses may be a safer option when local antibiotics are also used.

Adverse events related to the antibiotic treatment at 6 weeks, however, had occurred in 45.2% of those in the long-duration group, compared to 17.2% with short antibiotic regimens.The adverse events included 2 patients in the long-duration group with new onset C difficile infection; both severe and occurring within 6 weeks of surgery

Adverse symptoms were also reported between 3 and 6 months by 20.4% of those in the long-duration group and 8.5% with the short regimen. Other secondary outcome measures were comparable between groups, including the mean duration hospital stay of 14.8 days in the long-duration group and 11.9 days with the short regimen.

McNally and colleagues cite studies that associate the addition of local, implanted antibiotic treatment to systemic regimens with lower risk of treatment failure; and others that support the primary use of local antibiotic therapy for orthopedic infections.

"However, although data from the current trial support the utility of local antibiotics in reducing the need for prolonged systemic antibiotics, a substantial amount of high-quality data is needed before local therapy is adopted as the primary approach in clinical practice," McNally and colleagues indicate.


Reference
1. McNally M, Dudareva M, Kümin M, et al. Short or long antibiotic regimens in orthopedics. N Engl J Med. 2026, Online September 16; doi:10.1056/NEJMoa2506756

Related to this article

This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.